Device Trial Radar · NCT04295915
Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I Updates
Last checked: Nov 19, 2026Latest source record: Apr 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
731
Actual
Start
Mar 11, 2020
Primary completion
Dec 2, 2021
Study completion Apr 19, 2022
Sponsor
- Lead sponsor
- Accelerate Diagnostics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 5, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a performance and reproducibility study to validate new or updated antimicrobials on the Accelerate PhenoTest™ BC kit. The data from this study will be used to support the submission to the FDA for clearance in the US and for global registrations of the device intended for in vitro diagnostic use.
Conditions
- Bacteremia
Interventions
Specimens that meet inclusion criteriaDevice
Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Essential and categorical agreement with Clinical and Laboratory Standards Institute (CLSI) broth microdilution reference methodTime frame: Approximately 4 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Accelerate Diagnostics
Tucson, Arizona
Penn State-Hershey Medical Center
Hershey, Pennsylvania
Quest/med fusion
Lewisville, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.